Imexpharm Joint Stock Company organized the scientific workshop "Dual efficacy of pain relief - anti-inflammation in musculoskeletal disease control: From recommendations to practice" on 14/5, at White Palace Convention Center, TP HCM.

Ba Le Nu Minh Hoai, Deputy General Director of Imexpharm's Business Division, delivered the opening speech at the scientific workshop. Anh: Imexpharm

The program focused on updating treatment trends and practical drug counseling for musculoskeletal diseases. These conditions are increasingly prevalent and tend to affect younger individuals in Vietnam. According to organizers, the workshop was an opportunity to update treatment knowledge and connect experts, pharmacists, and pharmacy systems. This collaboration aims to enhance counseling effectiveness and help patients access suitable solutions.

At the event, Dr. Nguyen Dinh Thong, Specialist Level II and Head of the Internal Musculoskeletal Department at Nguyen Tri Phuong Hospital, presented on the use of Ibuprofen in treating musculoskeletal pain, titled "From guideline to practice". Additionally, Associate Professor, Doctor of Pharmacy Nguyen Tuan Dung, former Head of the Clinical Pharmacy Department at Ho Chi Minh City University of Medicine and Pharmacy, shared skills for counseling on Ibuprofen use at pharmacies.

Dr. Nguyen Dinh Thong, Specialist Level II and Head of the Internal Musculoskeletal Department at Nguyen Tri Phuong Hospital, shared insights on Ibuprofen use in treatment. Anh: Imexpharm

Pharmacist Lam Thi Ngoc Dung, Deputy Head of Marketing at Imexpharm, introduced a new product containing Ibuprofen, developed by the company. This product aims to support pain relief and anti-inflammation in musculoskeletal conditions. It can also be used for common pains like toothache, menstrual pain, or back pain.

"As musculoskeletal diseases continue to rise, placing pressure on the healthcare system, Imexpharm's launch of a new product for this group of conditions helps people proactively manage their health early, reducing the long-term treatment burden", Ms. Dung stated.

Ms. Dung noted that Imexpharm leverages its high-quality production capabilities, built on over 10 years of investment in EU-GMP certified factory systems and 20 years operating WHO-GMP certified facilities. The company is intensifying its investment in research and development (R&D) to align with the actual treatment needs of the population, particularly for prevalent conditions such as musculoskeletal, respiratory, digestive, and non-communicable diseases. She believes that many patients today seek not only treatment efficacy but also convenience, accessibility, and appropriate costs.

Therefore, alongside expanding its over-the-counter (OTC) product portfolio, Imexpharm also aims to develop quality treatment solutions at affordable prices, helping to reduce healthcare costs for Vietnamese people. Organizing and collaborating on medical workshops to update treatment knowledge for medical professionals is also part of its strategy to enhance community healthcare effectiveness.

Pharmacist Lam Thi Ngoc Dung (far right), Deputy Head of Marketing at Imexpharm, introduced a new product containing Ibuprofen developed by the company. Anh: Imexpharm

According to the World Health Organization (WHO), musculoskeletal diseases like back pain, neck pain, osteoarthritis, and rheumatoid arthritis affect nearly 2 billion people globally. These conditions are especially common in the working-age population. WHO indicates that these are also a leading cause for the increasing demand for rehabilitation today. Factors such as work pressure, inactivity, heavy lifting, or over-exercising without proper recovery can increase the risk of developing these diseases. Musculoskeletal conditions not only cause prolonged pain and restrict movement but also affect quality of life and mental well-being.

Hai My